Matrix metalloproteinase 9 is a mediator of epidermal growth factor-dependent E-cadherin loss in ovarian carcinoma cells

Karen Cowden Dahl, Jaime Symowicz, Yan Ning, Elisa Gutierrez, David A. Fishman, Brian P. Adley, M. Sharon Stack, Laurie G. Hudson

Research output: Contribution to journalArticle

109 Citations (Scopus)

Abstract

Epidermal growth factor (EGF) receptor (EGFR) is frequently elevated in epithelial ovarian cancer, and E-cadherin expression is often reduced in advanced disease. In this study, we investigated a mechanism by which EGFR activation promotes disruption of adherens junctions through induction of matrix metalloproteinase 9 (MMP-9). We show that EGFR activation down-modulates E-cadherin, and broad spectrum MMP inhibition ameliorates EGF-stimulated junctional disruption and loss of E-cadherin protein. MMP-9 involvement in EGF-dependent down-regulation of E-cadherin was determined by siRNA specifically directed against MMP-9. Furthermore, treatment with recombinant MMP-9 or transient expression of MMP-9 is sufficient to reduce E-cadherin levels in differentiated ovarian tumor cells. Stable overexpression of MMP-9 led to a loss of E-cadherin and junctional integrity, and promoted a migratory and invasive phenotype. Thus, elevated MMP-9 protein expression is sufficient for junctional disruption and loss of E-cadherin in these cells. The associations between EGFR activation, MMP-9 expression, and E-cadherin were investigated in human ovarian tumors and paired peritoneal metastases wherein immunohistochemical staining for activated (phospho) EGFR and MMP-9 colocalized with regions of reduced E-cadherin. These data suggest that regulation of MMP-9 by EGFR may represent a novel mechanism for down-modulation of E-cadherin in ovarian cancer.

Original languageEnglish (US)
Pages (from-to)4606-4613
Number of pages8
JournalCancer Research
Volume68
Issue number12
DOIs
StatePublished - Jun 15 2008
Externally publishedYes

Fingerprint

Matrix Metalloproteinase 9
Cadherins
Epidermal Growth Factor
Carcinoma
Epidermal Growth Factor Receptor
Adherens Junctions
Matrix Metalloproteinases
Ovarian Neoplasms
Small Interfering RNA
Neoplasms
Proteins
Down-Regulation
Staining and Labeling
Neoplasm Metastasis
Phenotype

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Cowden Dahl, K., Symowicz, J., Ning, Y., Gutierrez, E., Fishman, D. A., Adley, B. P., ... Hudson, L. G. (2008). Matrix metalloproteinase 9 is a mediator of epidermal growth factor-dependent E-cadherin loss in ovarian carcinoma cells. Cancer Research, 68(12), 4606-4613. https://doi.org/10.1158/0008-5472.CAN-07-5046

Matrix metalloproteinase 9 is a mediator of epidermal growth factor-dependent E-cadherin loss in ovarian carcinoma cells. / Cowden Dahl, Karen; Symowicz, Jaime; Ning, Yan; Gutierrez, Elisa; Fishman, David A.; Adley, Brian P.; Stack, M. Sharon; Hudson, Laurie G.

In: Cancer Research, Vol. 68, No. 12, 15.06.2008, p. 4606-4613.

Research output: Contribution to journalArticle

Cowden Dahl, K, Symowicz, J, Ning, Y, Gutierrez, E, Fishman, DA, Adley, BP, Stack, MS & Hudson, LG 2008, 'Matrix metalloproteinase 9 is a mediator of epidermal growth factor-dependent E-cadherin loss in ovarian carcinoma cells', Cancer Research, vol. 68, no. 12, pp. 4606-4613. https://doi.org/10.1158/0008-5472.CAN-07-5046
Cowden Dahl, Karen ; Symowicz, Jaime ; Ning, Yan ; Gutierrez, Elisa ; Fishman, David A. ; Adley, Brian P. ; Stack, M. Sharon ; Hudson, Laurie G. / Matrix metalloproteinase 9 is a mediator of epidermal growth factor-dependent E-cadherin loss in ovarian carcinoma cells. In: Cancer Research. 2008 ; Vol. 68, No. 12. pp. 4606-4613.
@article{2c2819178bbb4fa6b0a61d9a509389e4,
title = "Matrix metalloproteinase 9 is a mediator of epidermal growth factor-dependent E-cadherin loss in ovarian carcinoma cells",
abstract = "Epidermal growth factor (EGF) receptor (EGFR) is frequently elevated in epithelial ovarian cancer, and E-cadherin expression is often reduced in advanced disease. In this study, we investigated a mechanism by which EGFR activation promotes disruption of adherens junctions through induction of matrix metalloproteinase 9 (MMP-9). We show that EGFR activation down-modulates E-cadherin, and broad spectrum MMP inhibition ameliorates EGF-stimulated junctional disruption and loss of E-cadherin protein. MMP-9 involvement in EGF-dependent down-regulation of E-cadherin was determined by siRNA specifically directed against MMP-9. Furthermore, treatment with recombinant MMP-9 or transient expression of MMP-9 is sufficient to reduce E-cadherin levels in differentiated ovarian tumor cells. Stable overexpression of MMP-9 led to a loss of E-cadherin and junctional integrity, and promoted a migratory and invasive phenotype. Thus, elevated MMP-9 protein expression is sufficient for junctional disruption and loss of E-cadherin in these cells. The associations between EGFR activation, MMP-9 expression, and E-cadherin were investigated in human ovarian tumors and paired peritoneal metastases wherein immunohistochemical staining for activated (phospho) EGFR and MMP-9 colocalized with regions of reduced E-cadherin. These data suggest that regulation of MMP-9 by EGFR may represent a novel mechanism for down-modulation of E-cadherin in ovarian cancer.",
author = "{Cowden Dahl}, Karen and Jaime Symowicz and Yan Ning and Elisa Gutierrez and Fishman, {David A.} and Adley, {Brian P.} and Stack, {M. Sharon} and Hudson, {Laurie G.}",
year = "2008",
month = "6",
day = "15",
doi = "10.1158/0008-5472.CAN-07-5046",
language = "English (US)",
volume = "68",
pages = "4606--4613",
journal = "Journal of Cancer Research",
issn = "0099-7013",
publisher = "American Association for Cancer Research Inc.",
number = "12",

}

TY - JOUR

T1 - Matrix metalloproteinase 9 is a mediator of epidermal growth factor-dependent E-cadherin loss in ovarian carcinoma cells

AU - Cowden Dahl, Karen

AU - Symowicz, Jaime

AU - Ning, Yan

AU - Gutierrez, Elisa

AU - Fishman, David A.

AU - Adley, Brian P.

AU - Stack, M. Sharon

AU - Hudson, Laurie G.

PY - 2008/6/15

Y1 - 2008/6/15

N2 - Epidermal growth factor (EGF) receptor (EGFR) is frequently elevated in epithelial ovarian cancer, and E-cadherin expression is often reduced in advanced disease. In this study, we investigated a mechanism by which EGFR activation promotes disruption of adherens junctions through induction of matrix metalloproteinase 9 (MMP-9). We show that EGFR activation down-modulates E-cadherin, and broad spectrum MMP inhibition ameliorates EGF-stimulated junctional disruption and loss of E-cadherin protein. MMP-9 involvement in EGF-dependent down-regulation of E-cadherin was determined by siRNA specifically directed against MMP-9. Furthermore, treatment with recombinant MMP-9 or transient expression of MMP-9 is sufficient to reduce E-cadherin levels in differentiated ovarian tumor cells. Stable overexpression of MMP-9 led to a loss of E-cadherin and junctional integrity, and promoted a migratory and invasive phenotype. Thus, elevated MMP-9 protein expression is sufficient for junctional disruption and loss of E-cadherin in these cells. The associations between EGFR activation, MMP-9 expression, and E-cadherin were investigated in human ovarian tumors and paired peritoneal metastases wherein immunohistochemical staining for activated (phospho) EGFR and MMP-9 colocalized with regions of reduced E-cadherin. These data suggest that regulation of MMP-9 by EGFR may represent a novel mechanism for down-modulation of E-cadherin in ovarian cancer.

AB - Epidermal growth factor (EGF) receptor (EGFR) is frequently elevated in epithelial ovarian cancer, and E-cadherin expression is often reduced in advanced disease. In this study, we investigated a mechanism by which EGFR activation promotes disruption of adherens junctions through induction of matrix metalloproteinase 9 (MMP-9). We show that EGFR activation down-modulates E-cadherin, and broad spectrum MMP inhibition ameliorates EGF-stimulated junctional disruption and loss of E-cadherin protein. MMP-9 involvement in EGF-dependent down-regulation of E-cadherin was determined by siRNA specifically directed against MMP-9. Furthermore, treatment with recombinant MMP-9 or transient expression of MMP-9 is sufficient to reduce E-cadherin levels in differentiated ovarian tumor cells. Stable overexpression of MMP-9 led to a loss of E-cadherin and junctional integrity, and promoted a migratory and invasive phenotype. Thus, elevated MMP-9 protein expression is sufficient for junctional disruption and loss of E-cadherin in these cells. The associations between EGFR activation, MMP-9 expression, and E-cadherin were investigated in human ovarian tumors and paired peritoneal metastases wherein immunohistochemical staining for activated (phospho) EGFR and MMP-9 colocalized with regions of reduced E-cadherin. These data suggest that regulation of MMP-9 by EGFR may represent a novel mechanism for down-modulation of E-cadherin in ovarian cancer.

UR - http://www.scopus.com/inward/record.url?scp=49649098028&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=49649098028&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-07-5046

DO - 10.1158/0008-5472.CAN-07-5046

M3 - Article

C2 - 18559505

AN - SCOPUS:49649098028

VL - 68

SP - 4606

EP - 4613

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0099-7013

IS - 12

ER -